Drug Profile
Research programme: stem cell therapies - Ferrer
Alternative Names: FAB-111; FAB-112Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Ferrer
- Class Stem cell therapies
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Eye disorders in Spain (unspecified route)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Eye-disorders in Spain
- 21 Jan 2016 Preclinical trials in Eye disorders in Spain (unspecified route)